Vima LLC’s Definium Therapeutics DFTX Stock Holding History

Vima LLC’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-29	Closed	-$92	–	241
2024 Q1	$92	Buy	29 +10	+53%	+$57	﹤0.01%	411
2023 Q4	$70	Buy	+19	New	+$57	﹤0.01%	397

Other funds holding DFTX

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vima LLC's DFTX Position: Q2 2024 in Review

Vima LLC sold out of Definium Therapeutics (DFTX) in Q2 2024, closing a stake of 29 shares — an estimated $92 sold.

Vima LLC first reported a position in DFTX in Q4 2023 and held it in 2 quarters. The position peaked at $92 in Q1 2024. 151 funds tracked by Wall St. Rank hold DFTX as of Q2 2024.

Vima LLC reported no remaining Definium Therapeutics position as of Q2 2024 after selling out during the quarter.
Vima LLC sold 29 Definium Therapeutics shares in Q2 2024, an estimated $92.
Vima LLC first reported a position in Definium Therapeutics in Q4 2023 and held it in 2 quarters.
Vima LLC's Definium Therapeutics position peaked at $92 in Q1 2024.
151 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2024.

Based on Vima LLC's 13F filing for Q2 2024, filed 8 Aug 2024.